GERON CORP 8-K

What Happened
Geron Corporation (GERN) filed a Form 8-K on January 12, 2026 (Item 7.01) to disclose a press release announcing its 2026 financial guidance and business highlights. The announcement includes the company's expected RYTELO® net product revenue and projected total operating expenses for 2026. Geron also furnished a slide presentation for investor and analyst meetings at the 44th Annual J.P. Morgan Healthcare Conference (week of January 12, 2026).

Key Details

• Date filed: January 12, 2026 (Form 8-K, Item 7.01—Regulation FD disclosure).
• Content: Press release with 2026 financial guidance covering expected RYTELO® net product revenue and total operating expenses (Exhibit 99.1).
• Investor outreach: Corporate slides to be presented at the J.P. Morgan Healthcare Conference (Exhibit 99.2).
• Signature: Filing executed by Michelle Robertson, Executive Vice President, Chief Financial Officer and Treasurer.

Why It Matters
This filing provides the company’s forward-looking revenue and expense outlook for 2026, which investors can use to update revenue and profitability expectations for Geron and its RYTELO product. The furnished press release and JPM conference slides are the primary sources for the specific guidance figures—investors should review those exhibits for the detailed numeric guidance and any related assumptions. The Regulation FD disclosure ensures the information was made publicly available to all investors.